HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hamburg’s Public Farewell Includes Rallying Cry For FDA Power

This article was originally published in The Rose Sheet

Executive Summary

Outgoing commissioner gives a forceful defense of the agency’s regulatory authority and warns that lowering drug approval standards would be detrimental to both patients and industry.

You may also be interested in...



FDA Chief Scientist Ostroff Named Acting Head With Hamburg On Way Out

Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she’ll leave the agency in March with high drug approval numbers and praise from industry groups. Chief Scientist Stephen Ostroff has been named acting head, and some speculate that Robert Califf, newly appointed deputy commissioner for medical products and tobacco, is in line to succeed Hamburg on a permanent basis.

Priority Review Voucher Programs Poised For US Legislative Attention In 2020

Unless reauthorized by Congress, the rare pediatric disease program will begin to expire in September; renewal could bring bigger changes across the three PRV programs, including an FDA-requested clarification of biologic products eligible for vouchers and reforms suggested by sponsors and other stakeholders in a recent GAO report.


US Researchers Working Toward Universal Coronavirus Vaccine

The SARS-CoV-2 outbreak has the federal government working not only on a vaccine candidate specifically targeted at the novel coronavirus but also thinking more broadly about ways to head off future potential pandemics with emerging pathogens.

UsernamePublicRestriction

Register

RS019435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel